NEW YORK (GenomeWeb) – Sigma-Aldrich said today it will acquire Olink Bioscience's Duolink product portfolio.
Based on Olink's proximity ligation assay (PLA) technology, Duolink allows for detection of low-abundance proteins with higher specificity than conventional immunoassays.
The method uses pairs of antibodies attached to unique DNA sequences to detect proteins of interest. When the antibodies bind their targets, the attached DNA strands are brought into proximity and ligate, forming a new DNA amplicon that can then be quantified using real-time PCR. The quantity of the DNA corresponds to the quantity of the target protein.
Sigma-Aldrich has distributed Duolink reagents including pre-validated antibody pairs since 2013.
"The acquisition of Duolink allows Sigma-Aldrich to provide comprehensive solutions for enabling experimental reproducibility with continued reliability in supply and quality," Amanda Halford, vice president, academic research at Sigma-Aldrich, said in a statement.
In a statement, Olink CEO Jon Heimer said the company will now focus on development of its Proseek Multiplex product line, which is based on a similar underlying technology. Olink also plans to establish local commercial operations in Europe and North America, Heimer said.
Financial and other terms of the deal were not disclosed.